Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)

NCT06908785 | Recruiting

• 1 other identifier: CIR-ROTEM
• Study Type: observational
• Target: 330
• Locations: 1 country
• Sites: 11

Brief Summary

The assessment of post-procedural bleeding risk in cirrhosis remains a clinical challenge due to the lack of precise predictive tools and its high associated mortality. Although guidelines recommend a restrictive transfusion policy, adherence remains low, with a high rate of prophylactic transfusions despite unclear benefits. This multicenter, prospective, and observational study will evaluate the utility of ROTEM in bleeding risk stratification for cirrhotic patients with significant abnormalities in conventional hemostasis tests undergoing high-risk invasive procedures. The primary objective is to establish cut-off values with a high negative predictive value, optimizing transfusion decisions and reducing unnecessary blood product use. Additionally, the study will analyze the relationship between ROTEM, inflammation biomarkers, and coagulation factors, along with a cost-effectiveness analysis comparing different transfusion strategies. This will be the largest study to date assessing ROTEM in this setting, overcoming the limitations of previous studies, which have been mostly retrospective with heterogeneous populations and procedures. Its findings could contribute to the standardization of transfusion management in cirrhosis and improve healthcare resource efficiency. The widespread availability of ROTEM in other disciplines within the National Health System will facilitate its implementation in this clinical setting without requiring additional investment in equipment.

Conditions

Cirrhosis, Liver

Keywords

Hemorrhage; Viscoelastic tests; Rotational thromboelastometry

Outcome Measures

Primary Outcomes (1)

• Incidence of post-procedural bleeding events within 28 days

  Number of participants with bleeding events occurring within 28 days after undergoing a high-risk invasive procedure. Bleeding will be classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. ROTEM parameters (Clotting Time \[CT\], Clot Formation Time \[CFT\], Amplitude at 5/10 minutes \[A5, A10\], Maximum Clot Firmness \[MCF\], Maximum Lysis \[ML\], and Lysis Index at 30 minutes \[LI30\]) will be measured pre-procedure and analyzed to determine cut-off values with high negative predictive value for post-procedural bleeding.

  28 days after the procedure

Study Arms (1)

EXPERIMENTAL GROUP

cirrhosis undergoing invasive procedures

Device: Rotational thromboelastometry

Interventions

Rotational thromboelastometry DEVICE

rotem

EXPERIMENTAL GROUP

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with cirrhosis undergoing invasive procedures

You may qualify if:

• Age between 18 and 85 years.
• Clinical, analytical, elastographic, histological, and/or imaging criteria consistent with the diagnosis of hepatic cirrhosis.
• Undergoing a high-risk invasive procedure, either in an outpatient setting or during hospitalization.
• Platelet count below 50,000/μL or INR greater than 1.5 with a platelet count below 100,000/μL.
• Signature of informed consent.

You may not qualify if:

• Cirrhotic patients with acute-on-chronic liver failure (ACLF) as defined by EASL criteria, and patients admitted to Intensive Care Units. These patients are excluded because hemostatic alterations in ACLF and critically ill patients are different and more pronounced compared to those in outpatient or general medical ward settings.
• Chronic kidney disease stage ≥3.
• Presence and/or history of thromboembolic complications.
• Presence of non-hepatic tumors.
• Presence of any primary hematologic disease (including inherited coagulopathies or thrombophilia).
• Recent surgery (\<8 weeks).
• History of organ transplantation, including liver transplantation.
• Pregnancy.
• Use of anticoagulants, antiplatelet agents other than acetylsalicylic acid, and/or antifibrinolytic therapy.
• Active disseminated intravascular coagulation.

Sponsors & Collaborators

• Instituto de Investigación Marqués de Valdecilla: lead

Study Sites (11)

Hospital universitario Marques de Valdecilla

Santander, Cantabria, 39008, Spain

RECRUITING

Hospital General Universitario Dr. Balmis de Alicante

Alicante, Spain

RECRUITING

Hospital Clinic Barcelona

Barcelona, 08036, Spain

RECRUITING

. Hospital de la Santa Creu i Sant

Barcelona, 08041, Spain

RECRUITING

Hospital Universitario de Bellvitge

Barcelona, 08907, Spain

RECRUITING

Hospital Universitario de Cruces

Bilbao, 48903, Spain

RECRUITING

Hospital Universitario de Burgos

Burgos, Spain

RECRUITING

hospital Ramon y Cajal

Madrid, 28034, Spain

RECRUITING

Hospital La Paz

Madrid, Spain

RECRUITING

Huca

Oviedo, Spain

RECRUITING

Hospital General Universitario de Toledo

Toledo, 45007, Spain

RECRUITING

Related Publications (23)

• Zanetto A, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis. Hepatol Commun. 2020 Dec 12;5(2):272-282. doi: 10.1002/hep4.1641. eCollection 2021 Feb.

  PMID: 33553974 BACKGROUND

• European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022 May;76(5):1151-1184. doi: 10.1016/j.jhep.2021.09.003. Epub 2022 Mar 15.

  PMID: 35300861 BACKGROUND

• Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Jan;73(1):366-413. doi: 10.1002/hep.31646. Epub 2021 Jan 20. No abstract available.

  PMID: 33219529 BACKGROUND

• Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2019 Mar;17(4):595-606. doi: 10.1016/j.cgh.2018.09.043. Epub 2018 Sep 28. No abstract available.

  PMID: 30273751 BACKGROUND

• Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, Farias AQ, Mazo DF, Boike JR, Stine JG, Serper M, Pereira G, Mattos AZ, Marciano S, Davis JPE, Benitez C, Chadha R, Mendez-Sanchez N, deLemos AS, Mohanty A, Dirchwolf M, Fortune BE, Northup PG, Patrie JT, Caldwell SH. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study. Gastroenterology. 2023 Sep;165(3):717-732. doi: 10.1053/j.gastro.2023.05.046. Epub 2023 Jun 2.

  PMID: 37271290 BACKGROUND

• Pfisterer N, Schwarz M, Jachs M, Putre F, Ritt L, Mandorfer M, Madl C, Trauner M, Reiberger T. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int. 2023 Oct;17(5):1205-1214. doi: 10.1007/s12072-023-10515-y. Epub 2023 Apr 6.

  PMID: 37024710 BACKGROUND

• Ronca V, Barabino M, Santambrogio R, Opocher E, Hodson J, Bertolini E, Birocchi S, Piccolo G, Battezzati P, Cattaneo M, Podda GM. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. Hepatol Commun. 2022 Feb;6(2):423-434. doi: 10.1002/hep4.1806. Epub 2021 Oct 30.

  PMID: 34716696 BACKGROUND

• Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, Sacerdoti D, Andriulli A, Licata A, Pietrangelo A, Picardi A, Raimondo G, Violi F; PRO-LIVER Collaborators. Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. Am J Gastroenterol. 2018 Mar;113(3):368-375. doi: 10.1038/ajg.2017.457. Epub 2017 Dec 19.

  PMID: 29257146 BACKGROUND

• Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, Siena D, Caruso M, Ippolito A, Mannuccio PM, Andriulli A. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017 Mar;38:79-82. doi: 10.1016/j.ejim.2016.11.007. Epub 2016 Dec 15.

  PMID: 27989373 BACKGROUND

• Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology. 2008 May;47(5):1604-14. doi: 10.1002/hep.22216.

  PMID: 18393319 BACKGROUND

• Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010 Oct;8(10):899-902; quiz e109. doi: 10.1016/j.cgh.2010.06.018. Epub 2010 Jun 30.

  PMID: 20601131 BACKGROUND

• Montalva E, Rodriguez-Peralvarez M, Blasi A, Bonanad S, Gavin O, Hierro L, Llado L, Llop E, Pozo-Laderas JC, Colmenero J; on behalf of the Spanish Society of Liver Transplantation and the Spanish Society of Thrombosis and Haemostasis. Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation. Transplantation. 2022 Jun 1;106(6):1123-1131. doi: 10.1097/TP.0000000000004014. Epub 2022 Jan 4.

  PMID: 34999660 BACKGROUND

• Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis. 2016 May;48(5):455-467. doi: 10.1016/j.dld.2016.02.008. Epub 2016 Feb 27.

  PMID: 27012444 BACKGROUND

• Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020 Jan;115(1):18-40. doi: 10.14309/ajg.0000000000000486.

  PMID: 31895720 BACKGROUND

• Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, Wilkins LR, Sarode R, Weinberg I. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019 Aug;30(8):1168-1184.e1. doi: 10.1016/j.jvir.2019.04.017. Epub 2019 Jun 20. No abstract available.

  PMID: 31229333 BACKGROUND

• Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, Thachil J. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022 Jan;20(1):39-47. doi: 10.1111/jth.15562. Epub 2021 Nov 8.

  PMID: 34661370 BACKGROUND

• O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology. 2021 Nov;161(5):1615-1627.e1. doi: 10.1053/j.gastro.2021.08.015. Epub 2021 Sep 25. No abstract available.

  PMID: 34579936 BACKGROUND

• Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE; Bleeding in liver diseases investigatorsdagger; Bleeding in liver diseases investigators. Expert opinion on bleeding risk from invasive procedures in cirrhosis. JHEP Rep. 2023 Dec 19;6(3):100986. doi: 10.1016/j.jhepr.2023.100986. eCollection 2024 Mar.

  PMID: 38384669 BACKGROUND

• Desborough MJ, Hockley B, Sekhar M, Burroughs AK, Stanworth SJ, Jairath V; National Audit Collaborative. Patterns of blood component use in cirrhosis: a nationwide study. Liver Int. 2016 Apr;36(4):522-9. doi: 10.1111/liv.12999. Epub 2015 Nov 26.

  PMID: 26537012 BACKGROUND

• Lu Y, Sun G, Liu X, Liu Z, Tan J, Hao Y, Shan G, Luo Q, Wang D, Xing Y, Zhang X, Gong J, Stanworth SJ, Wang J, Wen A. Plasma Transfusion in Patients With Cirrhosis in China: A Retrospective Multicenter Cohort Study. Transfus Med Rev. 2017 Apr;31(2):107-112. doi: 10.1016/j.tmrv.2016.11.006. Epub 2016 Dec 2.

  PMID: 28063764 BACKGROUND

• Fortea JI, Puente A, Ezcurra I, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodriguez-Lope C, Huelin P, Casafont F, Fabrega E, Crespo J. Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. Dig Liver Dis. 2019 Jan;51(1):95-103. doi: 10.1016/j.dld.2018.06.003. Epub 2018 Jun 12.

  PMID: 29960901 BACKGROUND

• Tosetti G, Farina E, Caccia R, Sorge A, Berzuini A, Valenti L, Prati D, Tripodi A, Lampertico P, Primignani M. Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2022 Nov;54(11):1520-1526. doi: 10.1016/j.dld.2022.03.017. Epub 2022 Apr 23.

  PMID: 35474168 BACKGROUND

• Malleeswaran S, Sivajothi S, Reddy MS. Viscoelastic Monitoring in Liver Transplantation. Liver Transpl. 2022 Jun;28(6):1090-1102. doi: 10.1002/lt.26352. Epub 2021 Dec 3.

  PMID: 34724319 BACKGROUND

MeSH Terms

Conditions

Liver Cirrhosis; Hemorrhage

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

jose ignacio fortea

CONTACT

942202520; jifortea@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 25, 2025
• First Posted: April 3, 2025
• Study Start: March 1, 2025
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: April 3, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

ES (11)